Skip Navigation



Hum. Reprod. Advance Access published online on June 30, 2004
Human Reproduction, doi:10.1093/humrep/deh334
© 2004 by European Society of Human Reproduction and Embryology
This Article
Right arrow FREE Full Text (PDF ) Freely available
Right arrow All Versions of this Article:
19/8/1713    most recent
deh334v1
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Mochtar, M.H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Mochtar, M.H.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

Received February 20, 2004
Accepted April 30, 2004

Article

The effect of an individualized GnRH antagonist protocol on folliculogenesis in IVF/ICSI

M.H. Mochtar * on behalf of The Dutch Ganirelix Study Group *

* To whom correspondence should be addressed. E-mail: m.h.mochtar{at}amc.uva.nl.


  Abstract

BACKGROUND: The aim of this study was to assess the effect of an individualized GnRH antagonist regimen on folliculogenesis. METHODS: In a multicentre, randomized, clinical trial, IVF/ICSI patients were allocated to a standard regimen, in which they received daily 0.25 mg GnRH antagonist ganirelix (Orgalutran) from the 6th day of stimulation onward (fixed regimen n=102) or to an individualized regimen, in which IVF/ICSI patients received daily 0.25 mg GnRH antagonist starting on the day that the dominant follicle had reached a diameter of ≥15 mm (flexible regimen n=103). The primary endpoint was to assess the difference in the total number of oocytes. RESULTS: The mean (SD) number of retrieved oocytes was not statistically significantly different: 9.4 (5.8) in the flexible group versus 9.7 (6.5) in the fixed group. The clinical and ongoing pregnancy rates were 22.7 and 21.8% respectively in the flexible group versus 33 and 31.1% in the fixed group [relative rate ratio 0.69 (95% confidence interval 0.44-1.08) and 0.7 (0.44-1.12) respectively]. CONCLUSION: The individualized flexible regimen did not result in an increase in the total number of oocytes obtained.

Keywords: controlled ovarian stimulation; flexible start; follicle development; GnRH antagonist; IVF; ICSI.

*R.E.Bernardus, Gooi Noord Hospital, Blaricum; C.J.C.M.Hamilton, H.van Krevel, Jeroen Bosch Hospital, Den Bosch; B.Leerentveld, Isala Clinics, Zwolle; Y.M.van Kasteren, Medical Center Alkmaar, Alkmaar; M.A.H.M.Wiegerinck, Máxima Medical Centre, Veldhoven; P.Flierman, H.V.Verhoeve, OnzeLieveVrouwe Gasthuis, Amsterdam; and M.H.Mochtar, F.van der Veen, Academic Medical Center, Amsterdam


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
 Hum ReprodHome page
C. Blockeel, M. De Vos, W. Verpoest, D. Stoop, P. Haentjens, and P. Devroey
Can 200 IU of hCG replace recombinant FSH in the late follicular phase in a GnRH-antagonist cycle? A pilot study
Hum. Reprod., November 1, 2009; 24(11): 2910 - 2916.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
J.A. Huirne, R. Homburg, and C.B. Lambalk
Are GnRH antagonists comparable to agonists for use in IVF?
Hum. Reprod., November 1, 2007; 22(11): 2805 - 2813.
[Abstract] [Full Text] [PDF]

Home page
 Hum Reprod UpdateHome page
B.C. Tarlatzis, B.C. Fauser, E.M. Kolibianakis, K. Diedrich, P. Devroey, and , On Behalf of the Brussels GnRH Antagonist Consen
GnRH antagonists in ovarian stimulation for IVF
Hum. Reprod. Update, July 1, 2006; 12(4): 333 - 340.
[Abstract] [Full Text] [PDF]

Home page
 Hum ReprodHome page
M. H. Mochtar, M. Van Wely, and F. Van der Veen
Timing luteal phase support in GnRH agonist down-regulated IVF/embryo transfer cycles
Hum. Reprod., April 1, 2006; 21(4): 905 - 908.
[Abstract] [Full Text] [PDF]


Disclaimer: Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.